Compare Infosys Limited (INFY) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs Invesco Ltd. — how do they compare? Infosys Limited trades at $10.74 (market cap $41.74B), while Invesco Ltd. trades at $29.52 (market cap $13.28B). The key difference: Infosys Limited is far larger — about 3.1× Invesco Ltd.'s market cap, and Infosys Limited pays the higher dividend (4.89%). Which is the better fit depends on your goals — on Pluang, investors hold Infosys Limited for 27 Days and Invesco Ltd. for 77 Days on average.
| INFY | IVZ | |
|---|---|---|
Market Cap | $41.74B | $13.28B |
Volume | 31,354,285 | 3,698,033 |
Sector | Technology | Financials |
52-Week High | $20.22 | $33.31 |
52-Week Low | $10.49 | $22.44 |
Typical Hold Time | 27 Days | 77 Days |
Enterprise Value | $39.48B | $23.45B |
Dividend Yield | 4.89% | 2.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INFY trades at $10.73, up 1.71% today, with a bearish technical signal from moving averages. The company reported revenue of $19.28B in 2025, with a net income margin of 16.37% and a P/E ratio of 13.21. Recent earnings show mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026. News highlights strategic AI collaborations, such as with Columbia University and ABN Amro, aiming to drive innovation.
The outlook is cautious due to bearish technicals and a slight decline in 2026 cash flow projections. Analyst consensus is a 'Hold' with a $11.48 price target, suggesting limited upside. Risks include competitive pressures in IT services and macroeconomic headwinds affecting Western IT spending. The stock's current valuation appears reasonable, but growth catalysts from AI initiatives need to materialize to support a bullish case.
Invesco (IVZ) trades at $29.51, down 3.25% today, with bearish technical signals dominating. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026, while Q3 2026 results are pending. Despite negative net income margins in 2025, operating cash flow remains strong at $1.53 billion, and analyst consensus leans toward Hold with a $33.71 price target. Recent news highlights ETF expansions and AUM growth to $2.56 trillion in August 2026.
The outlook is cautious; IVZ faces profitability challenges with negative ROE and net margins, but solid cash flow and analyst buy ratings (42.86%) suggest recovery potential. Risks include earnings volatility and competitive ETF pressures, while institutional sentiment is neutral. The stock's current price near the low end of analyst targets ($28-$41) may appeal to value investors betting on operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
